

Ombretta Annibali

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3877737/publications.pdf>

Version: 2024-02-01

86
papers

842
citations

516710

16
h-index

580821

25
g-index

86
all docs

86
docs citations

86
times ranked

1496
citing authors

#	ARTICLE	IF	CITATIONS
1	Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 study. <i>Blood</i> , 2019, 134, 798-801.	1.4	53
2	Thrombocytopenia and hemorrhagic risk in cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 48, S13-S16.	4.4	47
3	Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. <i>Leukemia</i> , 2020, 34, 914-918.	7.2	46
4	Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2018, 132, 121-121.	1.4	46
5	Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis. <i>Blood Cancer Journal</i> , 2021, 11, 34.	6.2	39
6	Fibrin Glue Therapy for Severe Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1612-1617.	2.0	35
7	Novel <i>NPM1</i> exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML. <i>Blood</i> , 2021, 138, 2696-2701.	1.4	30
8	High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3120-3131.	1.6	29
9	Rituximab as Single Agent in Primary MALT Lymphoma of the Ocular Adnexa. <i>BioMed Research International</i> , 2015, 2015, 1-8.	1.9	26
10	Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 124, 41-50.	4.4	26
11	Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the Prospective International NF10 Study By Fondazione Italiana Linfomi. <i>Blood</i> , 2018, 132, 393-393.	1.4	26
12	Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 130, 27-35.	4.4	25
13	Cytogenetic abnormalities in adult non-promyelocytic acute myeloid leukemia: A concise review. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 331-346.	4.4	23
14	Early Diastolic Dysfunction after Cancer Chemotherapy: Primary Endpoint Results of a Multicenter Cardio-Oncology Study. <i>Chemotherapy</i> , 2018, 63, 55-63.	1.6	23
15	IgM multiple myeloma: Report of four cases and review of the literature. <i>Leukemia and Lymphoma</i> , 2006, 47, 1565-1569.	1.3	22
16	Treatment of 72 newly diagnosed Waldenström macroglobulinemia cases with oral melphalan, cyclophosphamide, and prednisone. <i>Cancer</i> , 2005, 103, 582-587.	4.1	21
17	Nonpegylated liposomal doxorubicin combination regimen (COMP) for the treatment of lymphoma patients with advanced age or cardiac comorbidity. <i>Hematological Oncology</i> , 2020, 38, 478-486.	1.7	15
18	Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2019, 134, 4322-4322.	1.4	15

#	ARTICLE	IF	CITATIONS
19	Review article: Mucosa-associated lymphoid tissue (MALT)-type lymphoma of ocular adnexa. Biology and treatment. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 100, 37-45.	4.4	13
20	Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Mintrial. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 197-205.	2.5	13
21	Pulmonary complications and survival after autologous stem cell transplantation: predictive role of pulmonary function and pneumotoxic medications. <i>European Respiratory Journal</i> , 2017, 49, 1601902.	6.7	12
22	Gonadal Function Recovery and Fertility in Women Treated with Chemo- and/or Radiotherapy for Hodgkin's and Non-Hodgkin Lymphoma. <i>Chemotherapy</i> , 2019, 64, 36-41.	1.6	12
23	Real-life analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1062-1068.	3.0	11
24	Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. <i>Blood Cancer Journal</i> , 2021, 11, 167.	6.2	11
25	Comparison between biosimilar filgrastim vs other granulocyte colony stimulating factor formulations (originator filgrastim, pegfilgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network. <i>British Journal of Haematology</i> , 2015, 169, 293-296.	2.5	10
26	Pharmacology of Cardio-Oncology: Chronotropic and Lusitropic Effects of B-Type Natriuretic Peptide in Cancer Patients with Early Diastolic Dysfunction Induced by Anthracycline or Nonanthracycline Chemotherapy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 366, 158-168.	2.5	10
27	A novel scoring system for TIGIT expression in classic Hodgkin lymphoma. <i>Scientific Reports</i> , 2021, 11, 7059.	3.3	10
28	Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience. <i>Hematological Oncology</i> , 2022, 40, 32-40.	1.7	10
29	Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?. <i>Journal of Bone Oncology</i> , 2021, 26, 100338.	2.4	9
30	Mutational profile of ZBTB16/RARA-positive acute myeloid leukemia. <i>Cancer Medicine</i> , 2021, 10, 3839-3847.	2.8	9
31	Methylenetetrahydrofolate reductase (MTHFR) C677T genetic polymorphism and late infarct-related coronary artery patency after thrombolysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 413-420.	2.1	8
32	Being in protective isolation following autologous haematopoietic stem cell transplantation: A phenomenological study. <i>Journal of Clinical Nursing</i> , 2017, 26, 4467-4478.	3.0	8
33	Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions. <i>Supportive Care in Cancer</i> , 2019, 27, 793-803.	2.2	8
34	PD-1/PD-L1 expression in extra-medullary lesions of multiple myeloma. <i>Leukemia Research</i> , 2016, 49, 98-101.	0.8	7
35	Factors influencing the perception of protective isolation in patients undergoing haematopoietic stem cell transplantation: A multicentre prospective study. <i>European Journal of Cancer Care</i> , 2019, 28, e13148.	1.5	7
36	Lenalidomide Maintenance with or without Prednisone in Newly Diagnosed Myeloma Patients: A Pooled Analysis. <i>Cancers</i> , 2019, 11, 1735.	3.7	7

#	ARTICLE	IF	CITATIONS
37	Development and initial validation of a questionnaire to assess patients' perception of protective isolation following haematopoietic stem cell transplantation. <i>European Journal of Cancer Care</i> , 2019, 28, e12955.	1.5	7
38	Long Term Outcome of Lenalidomide-Dexamethasone (Rd) Vs Melphalan-Lenalidomide-Prednisone (MPR) Vs Cyclophosphamide-Prednisone-Lenalidomide (CPR) As Induction Followed By Lenalidomide-Prednisone (RP) Vs Lenalidomide (R) As Maintenance in a Community-Based Newly Diagnosed Myeloma Population: Updated Analysis of EMN01 Phase III Study. <i>Blood</i> , 2017, 130, 901-901.	1.4	7
39	Relapse of IgA λ Multiple Myeloma Presenting as Obstructive Jaundice and Abdominal Pain. <i>Oncology Research and Treatment</i> , 2009, 32, 119-121.	1.2	6
40	The combination topotecan, temozolomide and dexamethasone associated with radiotherapy as treatment of central nervous system myeloma relapse. <i>International Journal of Hematology</i> , 2009, 89, 513-516.	1.6	6
41	Adherence to recommendation for chemotherapy-induced nausea and vomiting prophylaxis: the proposal of a score. <i>Supportive Care in Cancer</i> , 2013, 21, 5-6.	2.2	6
42	Quality-of-Life Monitoring During Hematopoietic Stem Cell Transplantation: Observations and a Suggestion From the Rome Transplant Network Quality of Life Working Party. <i>Journal of Pain and Symptom Management</i> , 2013, 45, e2-e3.	1.2	6
43	Impact of IFN lambda 3/4 single nucleotide polymorphisms on the cytomegalovirus reactivation in autologous stem cell transplant patients. <i>PLoS ONE</i> , 2018, 13, e0200221.	2.5	6
44	In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent. <i>Leukemia</i> , 2020, 34, 929-931.	7.2	6
45	Primary cardiac MYC/BCL6 double hit non-Hodgkin lymphoma. <i>Journal of Cardiology Cases</i> , 2018, 17, 103-106.	0.5	5
46	MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients. <i>British Journal of Haematology</i> , 2021, 195, 399-404.	2.5	5
47	Long-term quality of life of patients with acute promyelocytic leukemia treated with arsenic trioxide vs chemotherapy. <i>Blood Advances</i> , 2021, 5, 4370-4379.	5.2	5
48	Lenalidomide and Rituximab (ReRi) As Front Line Chemo-Free Therapy of Elderly Frail Patients with Diffuse Large B-Cells Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2019, 134, 2880-2880.	1.4	5
49	The Weekly Infusion of Bortezomib Reduces Peripheral Neuropathy.. <i>Blood</i> , 2009, 114, 3887-3887.	1.4	5
50	The Endogenous Lusitropic and Chronotropic Agent, B-Type Natriuretic Peptide, Limits Cardiac Troponin Release in Cancer Patients with an Early Impairment of Myocardial Relaxation Induced by Anthracyclines. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 367, 518-527.	2.5	4
51	Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group. <i>EJHaem</i> , 2022, 3, 121-128.	1.0	4
52	Bone marrow aspiration and biopsy-related pain management. <i>Annals of Hematology</i> , 2014, 93, 1061-2.	1.8	3
53	Preliminary results of a counselling programme for fertility preservation in female cancer patients: The experience of the GEMME DORMIENTI network. <i>European Journal of Cancer Care</i> , 2020, 29, e13174.	1.5	3
54	Matched-Pair Analysis of Transplant from Haploidentical, Unmanipulated Bone Marrow Donor versus HLA Identical Sibling for Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1113-1118.	2.0	3

#	ARTICLE	IF	CITATIONS
55	A Curious Novel Combination of Nucleophosmin (NPM1) Gene Mutations Leading to Aberrant Cytoplasmic Dislocation of NPM1 in Acute Myeloid Leukemia (AML). <i>Genes</i> , 2021, 12, 1426.	2.4	3
56	Recurrent Large Volume Silent Strokes in Sickle Cell Disease. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, e453-e455.	1.6	2
57	Patient-reported outcomes and quality of life assessment: New targets for new targeted therapy?. <i>Cancer</i> , 2016, 122, 1461-1462.	4.1	2
58	Chemotherapy-induced Nausea and Vomiting Prophylaxis in High-dose Melphalan and Autologous Stem Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 161-162.	0.4	2
59	Treatment and prognosis of primary pulmonary lymphoma: A long-term follow-up study. <i>European Journal of Haematology</i> , 2021, 106, 49-57.	2.2	2
60	Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols. <i>Acta Oncologica</i> , 2021, 60, 1520-1526.	1.8	2
61	May Tigit (T cell Ig and ITIM domain) Expression be a New Target for Hodgkin Lymphoma?. <i>Blood</i> , 2019, 134, 5235-5235.	1.4	2
62	The Accuracy of the International Myeloma Working Group Frailty Score in Capturing Health-Related Quality of Life Profile of Patients with Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 115-115.	1.4	2
63	Lenalidomide and Rituximab (ReRi) As Front-Line Chemo-Free Therapy for Elderly Frail Patients with Diffuse Large B-Cell Lymphoma. a Phase II Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2021, 138, 305-305.	1.4	2
64	Real Life™ experience in a difficult to treat™ patient population of non-Hodgkin lymphomas using the R-COMP regimen. <i>Leukemia and Lymphoma</i> , 2016, 57, 2919-2922.	1.3	1
65	Younger age at diagnosis of acute promyelocytic leukaemia is associated with better long-term cognitive functioning. <i>British Journal of Haematology</i> , 2020, 190, e304-e307.	2.5	1
66	Acute promyelocytic leukaemia long-term survivors: higher fatigue and greater overall symptom burden. <i>BMJ Supportive and Palliative Care</i> , 2020, , bmjspcare-2020-002281.	1.6	1
67	R-COMP Regimen in B Cell Non Hodgkin Lymphoma Patients with Cardiovascular Comorbidities. <i>Blood</i> , 2015, 126, 5096-5096.	1.4	1
68	Role of Congenital and Acquired Thrombophilic Factors in the Failure of Thrombolysis in Patients with Acute Myocardial Infarction.. <i>Blood</i> , 2004, 104, 2591-2591.	1.4	1
69	Long Term Follow-Up of 198 IgM Monoclonal Gammopathy of Undetermined Significance (MGUS).. <i>Blood</i> , 2004, 104, 4859-4859.	1.4	1
70	Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols. <i>Blood</i> , 2019, 134, 3845-3845.	1.4	1
71	Clinical Utility and Physician Perceptions of a Digital Platform for Electronic Patient-Reported Outcomes Monitoring in Patients with Hematologic Malignancies in Real-World Practice. <i>Blood</i> , 2021, 138, 4017-4017.	1.4	1
72	Multicenter Long Term Follow-up in Hairy Cell Leukemia Patients Treated with Cladribine: A Thirty-Year Experience. <i>Blood</i> , 2020, 136, 32-33.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Primary Bone Lymphoma of the Talus: A Challenging Diagnosis. <i>Tumori</i> , 2017, 103, S62-S65.	1.1	0
74	Gender, age and diagnosis effect on self-perceived pain in hematological patients: retrospective analysis of two case series. <i>Annals of Palliative Medicine</i> , 2018, 7, 484-486.	1.2	0
75	Patient characteristics and treatment patterns in multiple myeloma by treatment administration route and disease status: EASEMENT observational study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e276-e277.	0.4	0
76	Cytokines Behaviour in Multiple Myeloma during Zoledronic Acid Treatment.. <i>Blood</i> , 2004, 104, 4913-4913.	1.4	0
77	Type of Relapse in 91 Newly Diagnosed MM Patients Treated with High Dose Chemotherapy Followed by Autologous Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 5451-5451.	1.4	0
78	Role of the IL28B Rs12979860 C/T Polymorphism on the Incidence of Clinically-Active Cytomegalovirus Infection in Autologous Stem Cell Transplant Patients. <i>Blood</i> , 2015, 126, 3190-3190.	1.4	0
79	Different Levels of Alkaline Phosphatase (ALP) in Multiple Myeloma (MM) and SOLID Tumors with BONE Lesions. <i>Blood</i> , 2015, 126, 5359-5359.	1.4	0
80	Evolving Criteria of Donor Selection for Allogeneic Transplant in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2004-2004.	1.4	0
81	The Neutrophil/Lymphocyte Ratio (N/L) Is a Prognostic Marker in Patients with Diffuse Large B Cell Lymphoma: A Prospective Study from the Lazio Lymphoma Registry. <i>Blood</i> , 2016, 128, 3050-3050.	1.4	0
82	Immunotherapy in Multiple Myeloma: Experience of the Multiple Myeloma Gimema Lazio Group. <i>Blood</i> , 2018, 132, 5634-5634.	1.4	0
83	Mantle CELL Lymphoma (MCL) in Elderly Patients (PTs): The Experience in Real-Life of Rete Ematologica Laziale Linfomi (RELLI). <i>Blood</i> , 2019, 134, 5257-5257.	1.4	0
84	CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL). <i>Frontiers in Oncology</i> , 2021, 11, 730194.	2.8	0
85	Relapsed/Refractory Multiple Myeloma Patients. a Multicenter Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy. <i>Blood</i> , 2021, 138, 3755-3755.	1.4	0
86	IgM-Secreting Diffuse Large B-Cell Lymphoma (DLBCL) Is a Poor Prognostic Subset within the Non-Germinal-Centre-Type (GC-type): An Italian Multicentre Study. <i>Blood</i> , 2020, 136, 30-31.	1.4	0